FDA Over-the-Counter Drug Regulations

Over-the-counter (OTC) drug regulations govern the sale of medications available to consumers without a prescription, establishing the standards manufacturers must meet for safety, efficacy, and labeling before products can reach store shelves. The U.S. Food and Drug Administration administers this regulatory framework under authority granted by the Federal Food, Drug, and Cosmetic Act (FD&C Act). Because OTC drugs reach far larger consumer populations than most prescription products — the Consumer Healthcare Products Association estimates Americans conduct more than 6 billion treatment episodes annually using OTC medicines — the adequacy of this framework carries direct public health consequences. The rules covered here apply to drug products marketed legally in the United States domestic market, from pain relievers to antacids to topical antiseptics. For the broader regulatory environment in which OTC drugs operate, see the FDA Authority resource index.

Definition and scope

OTC drugs are defined under FDA regulations as drug products that are safe and effective for use by the general public without requiring supervision by a licensed healthcare practitioner (21 CFR Part 330). The regulatory scope encompasses finished dosage forms, active ingredient standards, permitted labeling claims, and manufacturing quality requirements.

The OTC drug market in the United States includes more than 300,000 marketed products (FDA OTC Drug Overview), though these products draw from a comparatively small set of active ingredients reviewed by FDA. The scope of OTC regulation extends to:

• Active ingredient identity, strength, and permitted concentration limits
• Drug Facts labeling format and content requirements
• Permitted dosage forms and dosing instructions
• Tamper-evident packaging requirements under 21 CFR Part 211
• Good Manufacturing Practice (GMP) compliance

Products that do not meet OTC monograph conditions or lack an approved New Drug Application (NDA) cannot be legally marketed. The FDA drug approval process determines whether a given product requires a full NDA or may qualify under OTC pathways.

How it works

OTC drug regulation operates through two distinct legal pathways, and the distinction between them determines a manufacturer's obligations before and after market entry.

OTC Monograph System (Traditional)

Historically, the primary pathway was the OTC Drug Review, a rulemaking process begun in 1972. Under this system, FDA evaluated active ingredients by therapeutic category and issued monographs — effectively public standards specifying which ingredients, at which concentrations, are Generally Recognized as Safe and Effective (GRASE) for defined indications. A product formulated strictly within the conditions of an applicable monograph could be marketed without a product-specific approval.

The CARES Act of 2020 (Public Law 116-136) fundamentally restructured this system by replacing the traditional notice-and-comment rulemaking process with an administrative order process. Under this reformed framework — now codified at 21 USC 355h — FDA issues OTC monograph orders (OMOs) that carry the force of law and can be updated more efficiently. Manufacturers must comply with applicable OMOs or obtain an approved NDA.

New Drug Application (NDA) Pathway

Products that do not conform to any existing monograph — including new active ingredients, new combinations, or new indications — must submit an NDA for OTC marketing. The NDA process for OTC drugs follows substantially the same evidentiary standards as prescription drug applications: clinical trial data demonstrating safety and efficacy, proposed labeling reviewed for consumer comprehensibility, and manufacturing quality documentation. The FDA New Drug Application process covers these requirements in detail.

Prescription-to-OTC Switch

A third mechanism governs products already approved as prescription drugs. Manufacturers may submit a supplemental NDA or a citizen petition requesting that FDA reclassify the product for OTC sale. FDA evaluates whether the drug can be used safely without professional supervision, whether consumers can self-diagnose the condition it treats, and whether the proposed labeling conveys sufficient information for appropriate self-use. Notable switches include the movement of loratadine (Claritin), omeprazole (Prilosec), and cetirizine (Zyrtec) from prescription to OTC status.

Common scenarios

Monograph-compliant product entry: A manufacturer formulating a new acetaminophen product at 325 mg per tablet, within the OTC monograph conditions for analgesics and antipyretics, may market the product after ensuring GMP compliance and correct Drug Facts labeling — no separate FDA approval is required at the product level.

Monograph deviation requiring NDA: A manufacturer wishing to market an analgesic at a concentration exceeding monograph limits, or combined with an active ingredient not permitted under the relevant OMO, must file an NDA and receive approval before marketing. Violations of this requirement constitute misbranding and adulteration under the FD&C Act, subject to FDA enforcement actions including seizure, injunction, and criminal prosecution.

Post-market labeling updates: Under the CARES Act framework, FDA can issue administrative orders updating OTC monograph conditions. Manufacturers must bring existing products into compliance within specified timeframes — typically 12 to 18 months depending on the order — or face market removal.

Adverse event reporting: OTC drug manufacturers are required under 21 CFR Part 310 to submit serious adverse event reports to FDA within 15 business days of receiving a report. The FDA adverse event reporting framework applies to both NDA-approved OTC products and monograph products.

Decision boundaries

The boundary between OTC and prescription classification, and between monograph eligibility and NDA requirement, turns on four criteria applied by FDA:

1. Safety profile without supervision — The drug's risk of harm from unsupervised use must be low. Drugs with narrow therapeutic indices, significant interaction risks, or requiring laboratory monitoring cannot qualify for OTC status.
2. Consumer self-diagnosis feasibility — The condition being treated must be one a layperson can reliably recognize without clinical evaluation. Conditions requiring differential diagnosis (e.g., distinguishing bacterial from viral infection) generally preclude OTC classification.
3. Labeling adequacy — Proposed labeling must communicate all necessary information for safe self-use. FDA may require consumer label comprehension studies for complex or higher-risk products.
4. Active ingredient monograph status — If the active ingredient is listed in a final OMO at the proposed concentration and indication, the product may use the monograph pathway. If the ingredient is not monograph-listed, or if the proposed use exceeds monograph conditions, an NDA is mandatory.

Monograph vs. NDA: Key Contrast

Products straddling the boundary — for example, a combination product with one monograph-compliant ingredient and one non-monograph ingredient — default to the NDA requirement for the entire product. The FDA combination products regulation page addresses products that present additional jurisdictional complexity when drug and device components are integrated.

Manufacturers seeking to understand labeling obligations for the prescription side of a Rx-to-OTC switch should also consult FDA prescription drug labeling requirements, which remain in effect for any version of the product still marketed under prescription status.